1,041.4%. That is CRISPR Therapeutics’ revenue growth versus the comparable period, taking the line from $892,000 to $10.2 million. For a biotech, that is not a rounding error. It is a sharp change in the commercial revenue line.

The losses also narrowed. Operating loss fell to $117.3 million from $229.3 million, while cash reached $291.3 million, up from $193.6 million. The surface reading is simple: CASGEVY revenue is arriving, and reported losses are smaller, even though operating cash use increased.

CRISPR attributes the revenue change to its share of sales from CASGEVY, the gene-editing treatment developed with Vertex. The company wrote in its latest 10-Q:

"The decrease was primarily attributable to an increase in our share of CASGEVY revenue."

10-Q 2026-08-03

That sentence is doing a lot of work. The revenue jump is not a broad-based sales story in the filing. It is a commercialization story concentrated in one collaboration, and it starts from a very small base.

The cash-flow comparison is less tidy. CRISPR said net cash used in operating activities increased by $24.6 million, even as net loss improved by about $130.5 million. The company gave a specific reason:

"The $24.6 million increase in net cash used in operating activities was primarily driven by a $57.4 million overall decrease in net changes of operating assets and liabilities, primarily driven by the timing of receipt of a $25.0 million milestone payment from Vertex which was paid in the first quarter of 2025, offset by a decrease in net loss of approximately $130.5 million."

10-Q 2026-08-03

In plain English, the reported loss got smaller, but the cash comparison lost a $25.0 million payment that had arrived in the prior-year period. Cash was higher at June 30, but the operating cash line still reflects payment timing as much as the underlying loss reduction. Biotech accounting: where one milestone can wander into the room and rearrange the furniture.

The company’s own annual results show why the base matters. Revenue was $3.5 million in 2025 after falling 90.6% from the prior year, following similarly sharp swings in earlier years. A $10.2 million period is a major change from that trough, but it does not yet make the revenue line smooth.

Shares diluted rose 10.8% in the latest reported period. On the latest annual facts, enterprise value was $4.1 billion against sales of $3.5 million, or 1170.7 times sales. That leaves the commercial ramp and the cash profile carrying rather different kinds of weight in how the filing is read.

Vertex is not a one-off name in CRISPR’s disclosures. The partner has appeared in 60 filings, and the latest report also says Vertex can conduct research in defined areas that could create additional milestone payments aggregating to high eight digits if the relevant program reaches approval, subject to limitations. The filing does not quantify when those payments would occur.

CRISPR’s next quarterly report will put the unresolved point on one line: whether CASGEVY revenue continues to rise alongside operating cash use that is less shaped by milestone timing. For now, the trade-off is clear enough: more product revenue, but cash flow with a calendar problem.

Source: CRISPR Therapeutics’ 10-Q filed August 3, 2026.